← Back to Search

Quit2Heal App for Smoking Cessation in Cancer Patients

Phase 3
Recruiting
Led By Jonathan Bricker
Research Sponsored by Fred Hutchinson Cancer Research Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Diagnosed with cancer within the past 24 months or currently receiving or planning to receive cancer treatment in the next 3 months
Age 18 or older
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at 3 months after randomization
Awards & highlights
No Placebo-Only Group
Pivotal Trial

Study Summary

This trial is testing whether the Quit2Heal app is more effective than the QuitGuide app in helping cancer patients quit smoking.

Who is the study for?
This trial is for adults over 18 in the US who have been diagnosed with cancer within the last two years or are undergoing treatment. Participants must be current smokers interested in quitting, willing to use a smartphone app for cessation, and able to complete surveys. They should not be using other quit-smoking programs or have used NCI's QuitGuide app.Check my eligibility
What is being tested?
The study compares two smoking cessation apps: Quit2Heal and QuitGuide. Both offer strategies to handle cravings, guides on quitting, staying smoke-free plans, and advice on choosing medications that help stop smoking. Patients will randomly receive one of these apps.See study design
What are the potential side effects?
Since this trial involves the use of smartphone applications rather than medication, there are no direct medical side effects associated with participation. However, participants may experience stress or frustration related to quitting smoking.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I was diagnosed with cancer in the last 2 years or will start treatment soon.
Select...
I am 18 years old or older.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at 3 months after randomization
This trial's timeline: 3 weeks for screening, Varies for treatment, and at 3 months after randomization for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of participants with 30-day cigarette smoking cessation at 12 months.
Secondary outcome measures
Number of participants with 30-day cigarette smoking cessation at 3 months.
Number of participants with 30-day cigarette smoking cessation at 6 months.

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Arm I (Quit2Heal app)Experimental Treatment2 Interventions
Patients receive the Quit2Heal app and are encouraged to use it frequently. During the entire 12-month follow-up period, the app will remain fully available anytime study participants wish to use it.
Group II: Arm II (QuitGuide app)Active Control2 Interventions
Patients receive the QuitGuide app and are encouraged to use it frequently. During the entire 12-month follow-up period, the app will remain fully available anytime study participants wish to use it.

Find a Location

Who is running the clinical trial?

Fred Hutchinson Cancer Research CenterLead Sponsor
443 Previous Clinical Trials
147,850 Total Patients Enrolled
Fred Hutchinson Cancer CenterLead Sponsor
555 Previous Clinical Trials
1,334,196 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,587 Previous Clinical Trials
41,242,080 Total Patients Enrolled
1 Trials studying Blood Cancers
70 Patients Enrolled for Blood Cancers

Media Library

Quit2Heal Smartphone App Clinical Trial Eligibility Overview. Trial Name: NCT04409236 — Phase 3
Blood Cancers Research Study Groups: Arm II (QuitGuide app), Arm I (Quit2Heal app)
Blood Cancers Clinical Trial 2023: Quit2Heal Smartphone App Highlights & Side Effects. Trial Name: NCT04409236 — Phase 3
Quit2Heal Smartphone App 2023 Treatment Timeline for Medical Study. Trial Name: NCT04409236 — Phase 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the risks associated with the Quit2Heal treatment program?

"Our analysts have rated Quit2Heal as a 3 in terms of safety. This is due to the fact that this is a Phase 3 trial, meaning that there is evidence of the medication's efficacy and repeated data sets affirming its safety."

Answered by AI

Is there still room for more study participants?

"The trial, which was created on 7/19/2021 and last updated 9/20/2022, is currently seeking participants, as is evident from the clinicaltrials.gov posting."

Answered by AI

Who else is applying?

What site did they apply to?
Fred Hutch/University of Washington Cancer Consortium
What portion of applicants met pre-screening criteria?
Did not meet criteria
~138 spots leftby May 2025